The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.65
Low: 1.55
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

5 Mar 2024 07:00

RNS Number : 5260F
IQ-AI Limited
05 March 2024
 

IQ-AI Limited

("IQ-AI" or the "Company")

Grant of Options

 

IQAI Limited (the "Company" or "IQAI"), announces that, the Company has granted options over a total of 18,905,474 ordinary shares of £0.01 each in the Company ("Ordinary Shares") to the Directors and employees to the Company (the "Options"). All Options are exercisable for 10 years from the date of grant.

 

In aggregate, 18,130,474 Options have been granted to Directors of the Company, as follows:

 

New options

Percentage of the current issued share capital of the Company

Trevor Brown

3,000,000

1.35

Mike Schmainda

8,630,474

3.89

Vinod Kaushal

6,000,000

2.71

Brett Skelly

500,000

0.23

The options granted to employees will vest annually in four equal tranches with the first quarter vesting upon grant. Half of Mr Kaushal's options will vest immediately, 1,500,000 options will vest after one year, and the balance will vest after two years. Mr Brown, Mr Schmainda and Mr Skelly's options will vest immediately.

 

Following the grant of the Options and historic options held by employees, the Company now has options outstanding over a total of 19,680,474 Ordinary Shares, equivalent to 8.88% of the Company's current issued share capital.

 

Further details of the Options can be found in the Notification of Dealing Form below.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Trevor Brown

Chief Executive Officer

Mike Schmainda

Executive Director

Vinod Kaushal

Non-Executive Director

Brett Skelly

Non-Executive Director

 

 

2

 

Reason for the notification

 

a)

 

Position/status

 

See 1a) above 

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

IQ-AI Limited

b)

 

LEI

 

213800SPW48XRJS2QH57

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary shares of £0.01 pence each in IQ-AI Limited

 

JE00BD4H0R42

b)

 

Nature of the transactions

 

Grant of options over ordinary shares

c)

 

Price(s) and volume(s)

 

 

Price: Exercise price of £0.019 per option

 

Trevor Brown

3,000,000

Mike Schmainda

8,630,474

Vinod Kaushal

6,000,000

Brett Skelly

500,000

d)

 

Aggregated information

- Aggregated volume

- Price

- Principal amount

 

N/A

 

e)

 

Dates of the transaction

 

5 March 2024

f)

Place of transaction

Outside a trading venue

 

 

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

**ENDS**

 For further information please contact:

 

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAKDLEDPLEFA
Date   Source Headline
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM
1st Jun 20207:00 amRNSIB Awarded $2.57m grant
19th May 20209:19 amRNSNotice of AGM
4th May 202010:04 amRNSFinal Results
30th Apr 20201:08 pmRNSDelay in Publishing Final Year Accounts
18th Mar 20202:34 pmRNSIB's Software featured in award-winning article
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:35 pmRNSPrice Monitoring Extension
28th Feb 20201:42 pmRNSTotal Voting Rights
5th Feb 20204:30 pmRNSConversion of Loan Notes - Correction
5th Feb 20203:20 pmRNSConversion of Loan Notes
27th Jan 20209:29 amRNSImaging Biometrics Adds to Development Team
20th Jan 20207:00 amRNSKFDA Clearance for StoneChecker Software
13th Jan 202011:35 amRNSExercise of Options
9th Jan 20207:00 amRNSImaging Biometrics Partners with AI Metrics
18th Dec 201912:46 pmRNSBoard Changes and Restructuring Initiatives
7th Nov 20197:01 amRNSInitiation of IB Stroke Project
2nd Oct 20192:00 pmRNSPrice Monitoring Extension
1st Oct 20192:05 pmRNSSecond Price Monitoring Extn
1st Oct 20192:00 pmRNSPrice Monitoring Extension
1st Oct 201911:05 amRNSSecond Price Monitoring Extn
1st Oct 201911:00 amRNSPrice Monitoring Extension
1st Oct 20199:05 amRNSSecond Price Monitoring Extn
1st Oct 20199:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.